FRANKFURT, March 19 (Reuters) - Bayer said on Tuesday that it would request regulatory approval for its menopausal relief drug after the daily pill was shown to ease hot flashes in a third late-stage trial.

Germany's Bayer said in a statement that a third Phase III trial with its elinzanetant drug candidate provided supporting data on efficacy and long-term safety.

Together with data from two earlier studies, Bayer would file requests for approval for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes, associated with menopause.

($1 = 0.9106 euros) (Reporting by Ludwig Burger Editing by Miranda Murray)